[First experience with a combined chemotherapeutic agent in pyelonephritis].
D000293:Adolescent; D000328:Adult; D000368:Aged; D062365:Aminobenzoates / Q000096:biosynthesis; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000963:Antimetabolites; D001437:Bacteriuria; D004357:Drug Synergism; D004754:Enterobacter; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005492:Folic Acid / Q000096:biosynthesis; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011512:Proteus Infections / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy* / Q000382:microbiology; D011743:Pyrimidines / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013420:Sulfamethoxazole / Q000627:therapeutic use*
D062365:Aminobenzoates; D000900:Anti-Bacterial Agents; D000963:Antimetabolites; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D005492:Folic Acid; D013420:Sulfamethoxazole
Erste Erfahrungen mit einem kombinierten Chemotherapeutikum bei Pyelonephritis.